magicmine/iStock via Getty Images
Crinetics Pharmaceuticals (NASDAQ:CRNX) traded higher after the company announced that a data readout accepted for a presentation at a medical event next month was released ahead of schedule.
The presentation comprised initial data from four patients who received the company’s oral product candidate CRN04894 in a Phase 2 trial for congenital adrenal hyperplasia, a group of disorders affecting adrenal glands.
Crinetics (CRNX) is expected to release the readout, including additional data, at the Endocrine Society’s annual meeting (ENDO 2024) on June 3, 2024, from 12:00 to 1:30 p.m. ET.
The four-patient readout indicates that CRN04894, also known as Atumelnant, at 80 mg once daily dosing led to “rapid, profound, and sustained suppression of A4 and 17-OHP,” researchers wrote, referring to the study’s main efficacy goals.
The experimental therapy was well tolerated without any serious or treatment-related adverse events, they added.
